Not mention possible NVS/cancer phase II news, new Licensing and collaborations, Orphan disease Phase III Behçet's uveitis eye disease enrollment, major analyst coverage ( after xoma beentraded above $5 for sometimes) etc etc
I think is still possible one big Pharm ( US or Takeda) partnership news. Why not? Think about it, if you are the big pharm and talked to XOMA long enough and try to make the good deal, what are you waiting for? XOMA nolonger that desperate needs cash, with more and more evidences show XOMA052 WORK; Orphan disease Phase II (POC, 7 for 7 100% efficacy), although Phase IIa not designed for efficacy, it showed very promising effect on Cardio-metabolic, even diabetic there is sign of improvement. Most importantly XOMA052 is safe and XOMA can wait.The later the bigger deal. imo
Phase 2a was set up for patients that their diabetes was already stablized between 7% and 10% ..they were already on diabetes medication metformin which lowers hbac1 on average 1,4%.. So they needed to test the saftey of adding xoma052 to this metformin ..the first 3 months safty was clearded and they got the green light to proceed and increase dosages ..from my take ..id hang on to your stock ..you will see some great results in coming months ..the point im waiting for is next summer ..but should get real info by end of march at latest
LOOK AT PHASE ONE ..XOMA052 PHASE 1 .....Glycemic control results: The greatest glycemic control, as measured by HbA1c and FBG, was observed at the 0.03 mg/kg multiple dose cohort, with every patient demonstrating improvement in HbA1c at day 56. The sustained reduction in FBG in this group resulted in a 29 mg/dL decrease at day 84, which equates to approximately a 1% reduction in HbA1c. Combined with the HbA1c data, this progressive reduction in FBG indicates that HbA1c should continue to decrease over time. http://www.drugs.com/clinical_trials/xom...